Literature DB >> 29496758

Cyclophosphamide in steroid refractory unclassifiable idiopathic interstitial pneumonia and interstitial pneumonia with autoimmune features (IPAF).

Ivo A Wiertz1, Coline H M van Moorsel1,2, Adriane D M Vorselaars1, Marian J R Quanjel1, Jan C Grutters1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29496758     DOI： 10.1183/13993003.02519-2017

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  5 in total

Review 1.  Interstitial Pneumonia With Autoimmune Features (IPAF).

Authors:  Ligia Fernandes; Mouhamad Nasser; Kais Ahmad; Vincent Cottin
Journal:  Front Med (Lausanne)       Date:  2019-09-27

2.  Krebs von den Lungen-6 and surfactant protein-A in interstitial pneumonia with autoimmune features.

Authors:  Mingshan Xue; Chuanxu Cai; Yifeng Zeng; Yifan Xu; Huai Chen; Haisheng Hu; Luqian Zhou; Baoqing Sun
Journal:  Medicine (Baltimore)       Date:  2021-01-29       Impact factor: 1.817

3.  Rituximab for interstitial pneumonia with autoimmune features at two medical centres.

Authors:  Kristin M D'Silva; Iazsmin Bauer Ventura; Marcy B Bolster; Flavia V Castelino; Amita Sharma; Brent P Little; Ayodeji Adegunsoye; Mary E Strek; Hyon Choi; Sydney B Montesi
Journal:  Rheumatol Adv Pract       Date:  2021-11-05

4.  Pirfenidone in Unclassifiable Interstitial Lung Disease: A Subgroup Analysis by Concomitant Mycophenolate Mofetil and/or Previous Corticosteroid Use.

Authors:  Michael Kreuter; Toby M Maher; Tamera J Corte; Maria Molina-Molina; Judit Axmann; Frank Gilberg; Klaus-Uwe Kirchgaessler; Vincent Cottin
Journal:  Adv Ther       Date:  2021-12-22       Impact factor: 3.845

Review 5.  Immunomodulatory treatment of interstitial lung disease.

Authors:  Laura van den Bosch; Fabrizio Luppi; Giovanni Ferrara; Marco Mura
Journal:  Ther Adv Respir Dis       Date:  2022 Jan-Dec       Impact factor: 5.158
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.